The Clot Thickens: Anticoagulation in ECMO

<p>Hannah M. Brokmeier, PharmD (<a href='https://twitter.com/hannahbrokmeier'>@hannahbrokmeier</a>) compares and contrasts the pharmacokinetic and pharmacodynamic properties of heparin and bivalirudin in extracorporeal support, identifies clinical scenarios that favor either heparin or bivalirudin for anticoagulation in ECMO and selects a preferred agent for ECMO when either heparin or bivalirudin are acceptable.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>